Sedron (alendronate)

PreclinicalSmall molecule

Sedron (alendronate) is one of 5 small molecule programs targeting Primary Hyperparathyroidism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary HyperparathyroidismActive, not recruiting

Primary HyperparathyroidismPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Primary Hyperparathyroidism

#DrugCompanyPhaseTrials

Sensipar

Amgen

Approved

10 2

Zometa

Pfizer

Approved

2 3

Fosamax

OOrganon and Co

Approved

2 4

Prolia

OOrganon and Co

Approved

1 5

Sedron (alendronate)

WWroclaw Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Hyperparathyroidism1 trial

OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism

Completed·WWroclaw Medical University·N/A·NCT01889134·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sedron (alendronate). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sedron (alendronate) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sedron (alendronate). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wroclaw Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWroclaw Medical University

Sedron (alendronate)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Primary Hyperparathyroidism1 trial

References

Drug Info

Quick Facts

Related News